Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Concerns about Lilly's Q3 update are overblown. Lilly's impressive growth story remains intact. The stock's valuation is attractive, factoring in anticipated growth over the next several years.

We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of ... to $27.12 billion justifies this substantial increase in stock price. With an EPS of $25.97 and a P/E ratio of 50 in 2028 ...

Everyone knows that big pharma companies like Eli Lilly (NYSE: LLY) need to get regulators to agree that their medicines are safe and effective before they can make any money. But regulators aren't ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company.

Shares of Eli Lilly and Co. slumped toward their biggest selloff in more than three years on Wednesday, after the drugmaker reported third-quarter results that missed expectations, due to big ...

A mixed set of profit reports from giants like Google’s parent company and Eli Lilly has stock indexes basically churning in ...